Clinical Cancer Genomics Gives Bioinformatics Businesses A Boost
This article was originally published in Start Up
Executive Summary
New products are combining genomic information with drug and clinical data to help oncologists make better treatment decisions. Buoyed largely by demand in oncology, is the time ripe to build lasting companies on bioinformatics platforms?
You may also be interested in...
Illumina Goes Consumer
Microarray and sequencing specialist Illumina has entered the consumer genomics game with a DTC personal genome sequencing service. It's distancing itself from regulators by partnering with others to handle any secondary data interpretation and dialog with customers, but cautious or not, by reaching out directly to the public, the move does turn on its head the traditional notion of first developing a technology tool for research, then moving on to more regimented clinical applications.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.